{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=9", "query": { "condition": "Cancer of the Stomach", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 951, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T14:14:05.676Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT01233505", "title": "Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Stomach", "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Ovarian Mucinous Cystadenocarcinoma", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gastric Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "veliparib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01233505" }, { "nct_id": "NCT04209465", "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "BDTX-189", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Black Diamond Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-19", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2025-04-17", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 24, "location_summary": "Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209465" }, { "nct_id": "NCT07807956", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Biliary Tract Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2026-09-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807956" }, { "nct_id": "NCT02207959", "title": "Gastric In Vivo Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Proflavine Hemisulphate salt", "type": "DRUG" }, { "name": "White-light examination", "type": "PROCEDURE" }, { "name": "Imaging with High Resolution Microendoscope", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Susana Gonzalez", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-01", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02207959" }, { "nct_id": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Bladder Cancer", "HER2-positive Solid Tumor" ], "interventions": [ { "name": "PRS-343 in Combination with Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-08-21", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650348" }, { "nct_id": "NCT02935634", "title": "A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Gastric Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "BMS-986205", "type": "BIOLOGICAL" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2016-11-29", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935634" }, { "nct_id": "NCT04929015", "title": "Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Appendix Carcinoma by AJCC V8 Stage", "Colorectal Carcinoma by AJCC V8 Stage", "Digestive System Neoplasm", "Esophageal Carcinoma by AJCC V8 Stage", "Gastric Carcinoma by AJCC V8 Stage", "Liver and Intrahepatic Bile Duct Carcinoma", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Biospecimen Collection - blood and tissue sample collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-04-29", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 2, "location_summary": "Livingston, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929015" }, { "nct_id": "NCT02576548", "title": "A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Expressing Breast or Gastric/Stomach Cancers" ], "interventions": [ { "name": "MEDI4276", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 47, "start_date": "2015-09-23", "completion_date": "2018-05-23", "has_results": false, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 5, "location_summary": "Stanford, California • Sarasota, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576548" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2021-08-27", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T14:14:05.676Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" } ] }